Advanced

NovoSeven in warfarin-treated patients

Berntorp, Erik LU ; Stigendal, L ; Lethagen, Stefan LU ; Olofsson, L and Hedner, U (2000) In Blood Coagulation and Fibrinolysis 11(Suppl 1). p.113-115
Abstract
Haemorrhages represent a major complication of treatment with vitamin K antagonists. In cases of severe bleeding, a prompt effect on the increased International Normalized Ratio value is vital to achieve haemostasis. As conventional treatment, that is plasma or plasma-derived concentrates, carries the risk of blood-borne virus transmission, new treatments are needed. An open, multicentre pilot trial is currently under way to determine the effect of recombinant activated factor VII (rFVIIa; NovoSeven) administered to patients experiencing a bleeding episode after receiving vitamin K antagonists. When rFVIIa was given to a patient with a warfarin-induced nosebleed, it had an immediate haemostatic effect and the International Normalized Ratio... (More)
Haemorrhages represent a major complication of treatment with vitamin K antagonists. In cases of severe bleeding, a prompt effect on the increased International Normalized Ratio value is vital to achieve haemostasis. As conventional treatment, that is plasma or plasma-derived concentrates, carries the risk of blood-borne virus transmission, new treatments are needed. An open, multicentre pilot trial is currently under way to determine the effect of recombinant activated factor VII (rFVIIa; NovoSeven) administered to patients experiencing a bleeding episode after receiving vitamin K antagonists. When rFVIIa was given to a patient with a warfarin-induced nosebleed, it had an immediate haemostatic effect and the International Normalized Ratio value virtually normalized. (Less)
Please use this url to cite or link to this publication:
author
; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Blood Coagulation and Fibrinolysis
volume
11
issue
Suppl 1
pages
113 - 115
publisher
Lippincott Williams & Wilkins
external identifiers
  • pmid:10850575
  • scopus:0034080555
ISSN
1473-5733
language
English
LU publication?
yes
additional info
The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Clinical Coagulation Research Unit (013242510), Emergency medicine/Medicine/Surgery (013240200)
id
03fe2c0f-ad77-446e-818d-8e71edebb945 (old id 1117572)
date added to LUP
2016-04-01 11:49:44
date last changed
2021-01-06 03:09:01
@article{03fe2c0f-ad77-446e-818d-8e71edebb945,
  abstract     = {Haemorrhages represent a major complication of treatment with vitamin K antagonists. In cases of severe bleeding, a prompt effect on the increased International Normalized Ratio value is vital to achieve haemostasis. As conventional treatment, that is plasma or plasma-derived concentrates, carries the risk of blood-borne virus transmission, new treatments are needed. An open, multicentre pilot trial is currently under way to determine the effect of recombinant activated factor VII (rFVIIa; NovoSeven) administered to patients experiencing a bleeding episode after receiving vitamin K antagonists. When rFVIIa was given to a patient with a warfarin-induced nosebleed, it had an immediate haemostatic effect and the International Normalized Ratio value virtually normalized.},
  author       = {Berntorp, Erik and Stigendal, L and Lethagen, Stefan and Olofsson, L and Hedner, U},
  issn         = {1473-5733},
  language     = {eng},
  number       = {Suppl 1},
  pages        = {113--115},
  publisher    = {Lippincott Williams & Wilkins},
  series       = {Blood Coagulation and Fibrinolysis},
  title        = {NovoSeven in warfarin-treated patients},
  volume       = {11},
  year         = {2000},
}